Author: Claude (AI), from PubMed abstracts · Reviewed by: Dr Mina Abdelmseih · Reviewed: 2026-11-15 · Review due: 2027-11-15

Educational content only. Not personalised medical advice. Clinical decisions remain the responsibility of the treating clinician.

Conjunctival melanoma

Conjunctival melanoma is a rare but sight- and life-threatening malignancy, accounting for 2%-5% of ocular tumours [S2]. It is often misdiagnosed or overlooked, and metastatic risk is as high as 30% [S8] [S10]. Early detection and controlled "no-touch" excision at an experienced centre are central to good outcomes [S4] [S8].

Key points - Global incidence is about 1 in a million and rising, especially over 65 years of age [S10]; it is rare in non-Caucasian populations [S2]. - Primary acquired melanosis (PAM) can give rise to conjunctival melanoma [S6]. - Early-stage disease is treated by wide local excision with cryotherapy to the margins and adjuvant therapy [S5]. - Topical mitomycin C and interferon alfa-2b are used as primary or adjuvant treatment, with overall remission of 74.1% in a systematic review of case-level data [S12]. - Evidence is limited: there is no standardised treatment [S10].

Evidence last checked: 2026-10-17 (PubMed abstracts).

Red flags

• A pigmented conjunctival mass or naevus with recent growth or change. This was the usual presentation in children and adolescents [S4].
• Late presentation. In a Nigerian series of six patients, all presented with pigmented ocular surface growths and half required orbital exenteration; three abandoned treatment [S1].
• Metastatic risk. Risk depends on tumour origin, AJCC classification, biomarkers and management technique [S8].
• Local recurrence. Recurrence and metastasis are more frequent than with other conjunctival neoplasms [S7].

Recognise it

• Conjunctival melanoma arises from the bulbar and palpebral conjunctiva and the caruncle [S5].
• PAM is acquired conjunctival pigmentation that can precede melanoma [S6].
• Incidence in Caucasian populations is 0.2-0.8 per million [S2]. Rarity in darker-skinned populations [S1] [S2] should not exclude the diagnosis.

Confirm it

• Excision biopsy provided both diagnosis and management in all reported paediatric cases [S4]; incision biopsy was used in one Nigerian patient [S1].
• Staging uses the AJCC classification; molecular biomarkers predict prognosis [S8].
• Sentinel lymph node biopsy is positive in 11%-13% of cases, including small tumours, but there is not enough evidence to make it mandatory [S3].

Manage it

Before acting on this section, check the national and local guidelines, product information and regulatory approvals that apply where you practise. See the medical disclaimer.

Tier A (primary care / no specialist)

• Refer any new, growing or changing pigmented conjunctival lesion to an eye clinic (see Refer when) [S4].
• Do not attempt removal.

Tier B (general eye clinic)

• Document the lesion with a photograph if possible and refer to an experienced centre; outcomes were better where "no-touch" excision was done in a specialist setting [S4] [S8].
• Avoid incisional or piecemeal surgery outside a specialist setting; management technique influences metastatic risk [S8].

Tier C (specialist centre)

1. Surgery. Small tumours: "no-touch" excision and cryotherapy at an experienced centre can give excellent outcomes [S8]. Early-stage disease: wide local excision, cryotherapy to the margins and adjuvant therapy [S5].
2. Topical chemotherapy. In 116 cases, primary mitomycin C achieved 60.7% remission and adjuvant mitomycin C 68.8%; interferon alfa-2b achieved 87.5% with fewer adverse effects [S12]. Primary mitomycin C suited diffuse, superficial and intraepithelial disease; adjuvant use suited nodular and invasive lesions [S12]. Interferon is the preferred adjuvant for PAM and melanoma in case-series evidence [S6]. Concentrations and regimens are not covered here; follow local protocols.
3. Radiotherapy. Proton beam therapy (6 retrospective series, 240 melanomas and 51 squamous cell carcinomas) gave 5-year overall survival of 78%, with sicca symptoms in 52% and cataract in 19%; certainty is low [S11].
4. Locally advanced and metastatic disease. Checkpoint inhibitors have been used to avoid orbital exenteration and for metastatic disease, but data come from case reports and small series [S7]. In pooled cases, combined BRAF/MEK inhibitors gave complete response in 6 of 18, and immunotherapy complete response in 12 of 44 [S9]. BRAF, NRAS and NF1 mutations are potential targets [S5]. Interferon combined with systemic immunotherapy may be an alternative to exenteration [S6].

Refer when

Pitfalls

• Dismissing a pigmented lesion as a benign naevus without checking for recent change [S4] [S10].
• Partial excision outside a specialist centre [S8].
• Assuming the disease cannot occur in darker-skinned patients [S1].
• Losing patients to follow-up after surgery: treatment abandonment was common in one Nigerian series [S1].

Evidence notes

• Thin evidence: no RCTs or guidelines were found; most sources are narrative reviews and case series.
• Systemic therapy response data are from small, selected case series with short follow-up [S9].
• The proton beam meta-analysis mixes melanoma and squamous cell carcinoma [S11].
• Not covered by these sources: detailed clinical signs separating naevus, PAM and melanoma, topical chemotherapy doses, surveillance schedules, and evidence-based referral timings.

Related articles

• Ocular surface squamous neoplasia
• Uveal melanoma: diagnosis and primary treatment

References

See the numbered source list below. Each marker [S#] links to its PubMed and DOI record.